(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel...
Stats | |
---|---|
本日の出来高 | 15 210.00 |
平均出来高 | 23 488.00 |
時価総額 | 40.57M |
EPS | $0 ( 2024-03-12 ) |
次の収益日 | ( $0 ) 2024-06-11 |
Last Dividend | $0.0200 ( 2009-12-18 ) |
Next Dividend | $0 ( N/A ) |
P/E | 17.05 |
ATR14 | $0.0220 (1.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Jonas Howard S | Buy | 348 259 | Class B Common Stock, par value $.01 per share |
2024-04-04 | Jonas Howard S | Sell | 348 259 | Class B Common Stock, par value $.01 per share |
2024-03-21 | Conkling William | Buy | 15 473 | Class B Common Stock, par value $.01 per share |
2024-03-21 | Polinsky David | Sell | 2 300 | Class B Common Stock, par value $.01 per share |
2024-01-30 | Jonas Howard S | Buy | 348 259 | Class B Common Stock, par value $.01 per share |
INSIDER POWER |
---|
52.60 |
Last 99 transactions |
Buy: 18 593 840 | Sell: 14 829 947 |
Rafael Holdings Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Rafael Holdings Inc 財務諸表
Annual | 2023 |
収益: | $279 000 |
総利益: | $201 000 (72.04 %) |
EPS: | $-0.0806 |
FY | 2023 |
収益: | $279 000 |
総利益: | $201 000 (72.04 %) |
EPS: | $-0.0806 |
FY | 2022 |
収益: | $410 000 |
総利益: | $338 000 (82.44 %) |
EPS: | $-6.31 |
FY | 2021 |
収益: | $3.97M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.490 |
Financial Reports:
No articles found.
Rafael Holdings Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0200 | 2009-06-19 |
Last Dividend | $0.0200 | 2009-12-18 |
Next Dividend | $0 | N/A |
Payout Date | 2009-12-31 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.0400 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.83 | -- |
Div. Sustainability Score | 4.90 | |
Div.Growth Potential Score | 0.471 | |
Div. Directional Score | 2.69 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 7.77 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0201 | 1.200 | 9.33 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0213 | 1.500 | -0.875 | -1.312 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 23.01 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 22.86 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.19 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0160 | -1.500 | 9.73 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -7.98 | 1.000 | -4.07 | -4.07 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.314 | 2.00 | -0.105 | -0.209 | [0 - 30] |
freeCashFlowPerShareTTM | 1.775 | 2.00 | 9.11 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0162 | -1.500 | 9.94 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.665 | 1.000 | 2.24 | 2.24 | [0.2 - 0.8] |
operatingProfitMarginTTM | -40.96 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.37 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00259 | 0.800 | -3.32 | -2.65 | [0.5 - 2] |
Total Score | 4.90 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 18.85 | 1.000 | 8.20 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0213 | 2.50 | -0.562 | -1.312 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.775 | 2.00 | 9.41 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.314 | 2.00 | -0.105 | -0.209 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.313 | 1.500 | -1.246 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -27.00 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | 0.471 |
Rafael Holdings Inc
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。